Physician profile
Ajinder S Dhatt
NPI 1851597793
$3,290.94
in general payments reported to CMS, 2019-2025
21 companies · $803 in 2025
The $803 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $174 · 2021: $211 · 2022: $446 · 2023: $407 · 2024: $749 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,959.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $661.70 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $605.13 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $574.49 | 2019-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $221.56 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $198.71 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $163.41 | 2020-2024 | Trintellix |
| Axsome Therapeutics, INC. | $156.07 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $89.02 | 2019-2023 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $85.96 | 2022 | |
| Vanda Pharmaceuticals INC. | $83.96 | 2022-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $76.06 | 2019-2025 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $74.12 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.60 | 2025 | Caplyta |
| Corium, LLC | $50.59 | 2022-2023 | Azstarys |
| Lundbeck LLC | $49.99 | 2020-2024 | Abilify Asimtufii |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $32.41 | 2024 | Xelstrym |
| Allergan, INC. | $29.99 | 2019 | |
| Brainsway USA INC | $21.24 | 2023 | |
| Collegium Pharmaceutical, INC. | $19.97 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $18.42 | 2020 | |
| Tris Pharma INC | $13.54 | 2023 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajinder Dhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.